Market Cap 394.69B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 23.70
Forward PE 21.03
Profit Margin 7.59%
Debt to Equity Ratio -26.45
Volume 6,405,940
Avg Vol 5,715,906
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 67%
Beta 0.36
Analysts Strong Sell
Price Target $246.08

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
SimpleWinningSetups
SimpleWinningSetups Dec. 16 at 7:45 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $220.00 Put · DEC 26, 2025 Exp Entry Price: $1.99 - $2.17 Exit Price Target: $4.00 Profit Margin: +101% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
V9RDPUMA
V9RDPUMA Dec. 16 at 7:38 PM
$ABBV Source of funds, POS
0 · Reply
Godreal1
Godreal1 Dec. 16 at 6:33 PM
$ABBV this stock is a joke been droppping all day ! And I know it’s had great news for the last two week barely move smh
0 · Reply
Czreri1
Czreri1 Dec. 16 at 5:55 PM
$ABBV this stock is a joke. Literally a prime example of manipulation.
0 · Reply
RodTownsend
RodTownsend Dec. 16 at 5:44 PM
$ABBV 🔥
0 · Reply
Longbuy1
Longbuy1 Dec. 16 at 4:50 PM
$SLS $ Meetings with $PFE, $ABBV is going to step up. Bidding war upcoming for BO.
1 · Reply
V9RDPUMA
V9RDPUMA Dec. 16 at 3:16 PM
$ABBV Must have been a upgrade today
0 · Reply
Longbuy1
Longbuy1 Dec. 16 at 2:38 PM
$SLS 2.15+, a day late but that's ok. If it hits 2.50 + you know somebody knows something and shits gonna get real. $ABBV come and buy us ANBV.
0 · Reply
SSmicrocap
SSmicrocap Dec. 16 at 2:37 PM
$ABBV massive dump too easyyyyy
0 · Reply
ZacksResearch
ZacksResearch Dec. 16 at 2:00 PM
$ABBV is on a roll — but is it enough to fend off fierce competition? 💪 📈 Its pipeline spans Rinvoq, tavapadon, and PVEK, potentially driving growth with key regulatory milestones on the horizon. 🤝 Over 30 M&A transactions since 2024 have diversified its pipeline, strengthening its therapeutic footprint. Discover how these strategies position AbbVie in the competitive landscape 👉 https://www.zacks.com/stock/news/2804834/how-abbvies-pipeline-is-lining-up-key-product-launches?cid=sm-stocktwits-2-2804834-body-24944&ADID=SYND_STOCKTWITS_TWEET_2_2804834_BODY_24944
0 · Reply
Latest News on ABBV
My Top 3 Healthcare Stocks to Buy in 2026

Dec 13, 2025, 2:37 PM EST - 3 days ago

My Top 3 Healthcare Stocks to Buy in 2026

ISRG LLY


The Smartest Dividend Stocks to Buy With $5,000 Right Now

Dec 12, 2025, 4:00 AM EST - 4 days ago

The Smartest Dividend Stocks to Buy With $5,000 Right Now

BAC EPD


Is AbbVie Stock Too Cheap to Ignore at Today's Price?

Dec 11, 2025, 11:06 AM EST - 5 days ago

Is AbbVie Stock Too Cheap to Ignore at Today's Price?


AbbVie: Unique Mix Of Growth And Value

Dec 10, 2025, 8:01 PM EST - 6 days ago

AbbVie: Unique Mix Of Growth And Value


3 Top Dividend Stocks to Buy in December

Dec 9, 2025, 4:44 AM EST - 7 days ago

3 Top Dividend Stocks to Buy in December

ARCC ENB


Could Buying AbbVie Today Set You Up for Life?

Dec 4, 2025, 9:15 AM EST - 12 days ago

Could Buying AbbVie Today Set You Up for Life?


2 Top Dividend Stocks to Buy Now and Hold For a Decade

Dec 2, 2025, 7:44 AM EST - 14 days ago

2 Top Dividend Stocks to Buy Now and Hold For a Decade

PFE


Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 17 days ago

Best Dividend Aristocrats For December 2025

ABT ADM ADP AFL ALB AMCR AOS


8 Dividend Stocks Every Investor Should Consider

Nov 28, 2025, 5:30 AM EST - 18 days ago

8 Dividend Stocks Every Investor Should Consider

AXP COST JPM NVDA PFE PM SPGI


5 Dividend Stocks to Hold for the Next 10 Years

Nov 24, 2025, 7:25 AM EST - 22 days ago

5 Dividend Stocks to Hold for the Next 10 Years

ARCC ENB O VZ


AbbVie Stock Falls 4% -- What Investors Need to Know

Nov 17, 2025, 7:17 AM EST - 4 weeks ago

AbbVie Stock Falls 4% -- What Investors Need to Know


2 Strong Healthcare Stock Picks for Dividend Investors

Nov 13, 2025, 3:55 AM EST - 4 weeks ago

2 Strong Healthcare Stock Picks for Dividend Investors

JNJ


AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 3:06 PM EST - 4 weeks ago

AbbVie Shares Rise To Intraday High After Key Trading Signal


AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 11, 2025, 10:40 PM EST - 4 weeks ago

AbbVie Has Many Bullish Attributes (Technical Analysis)


Three Healthcare Buys That Wall Street Loves

Nov 11, 2025, 10:50 AM EST - 5 weeks ago

Three Healthcare Buys That Wall Street Loves

AMGN LLY


5 Top Stocks to Buy in November

Nov 11, 2025, 8:49 AM EST - 5 weeks ago

5 Top Stocks to Buy in November


Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

Nov 8, 2025, 6:38 AM EST - 5 weeks ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE


3 Dividend Stocks Down 11%, 29%, and 41% to Buy in November

Nov 6, 2025, 8:45 AM EST - 5 weeks ago

3 Dividend Stocks Down 11%, 29%, and 41% to Buy in November

CL ZTS


My Favorite Dividend King to Buy in November

Nov 3, 2025, 7:30 AM EST - 6 weeks ago

My Favorite Dividend King to Buy in November


2 Magnificent Dividend Stocks to Buy and Hold Forever

Nov 2, 2025, 9:15 AM EST - 6 weeks ago

2 Magnificent Dividend Stocks to Buy and Hold Forever

ZTS


Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 6 weeks ago

Best Dividend Aristocrats For November 2025

ABT ADM ADP AMCR AOS ATO BDX


Why AbbVie Stock Flopped on Friday

Nov 1, 2025, 6:15 AM EDT - 6 weeks ago

Why AbbVie Stock Flopped on Friday


AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

Oct 31, 2025, 3:56 PM EDT - 6 weeks ago

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript


SimpleWinningSetups
SimpleWinningSetups Dec. 16 at 7:45 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $220.00 Put · DEC 26, 2025 Exp Entry Price: $1.99 - $2.17 Exit Price Target: $4.00 Profit Margin: +101% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
V9RDPUMA
V9RDPUMA Dec. 16 at 7:38 PM
$ABBV Source of funds, POS
0 · Reply
Godreal1
Godreal1 Dec. 16 at 6:33 PM
$ABBV this stock is a joke been droppping all day ! And I know it’s had great news for the last two week barely move smh
0 · Reply
Czreri1
Czreri1 Dec. 16 at 5:55 PM
$ABBV this stock is a joke. Literally a prime example of manipulation.
0 · Reply
RodTownsend
RodTownsend Dec. 16 at 5:44 PM
$ABBV 🔥
0 · Reply
Longbuy1
Longbuy1 Dec. 16 at 4:50 PM
$SLS $ Meetings with $PFE, $ABBV is going to step up. Bidding war upcoming for BO.
1 · Reply
V9RDPUMA
V9RDPUMA Dec. 16 at 3:16 PM
$ABBV Must have been a upgrade today
0 · Reply
Longbuy1
Longbuy1 Dec. 16 at 2:38 PM
$SLS 2.15+, a day late but that's ok. If it hits 2.50 + you know somebody knows something and shits gonna get real. $ABBV come and buy us ANBV.
0 · Reply
SSmicrocap
SSmicrocap Dec. 16 at 2:37 PM
$ABBV massive dump too easyyyyy
0 · Reply
ZacksResearch
ZacksResearch Dec. 16 at 2:00 PM
$ABBV is on a roll — but is it enough to fend off fierce competition? 💪 📈 Its pipeline spans Rinvoq, tavapadon, and PVEK, potentially driving growth with key regulatory milestones on the horizon. 🤝 Over 30 M&A transactions since 2024 have diversified its pipeline, strengthening its therapeutic footprint. Discover how these strategies position AbbVie in the competitive landscape 👉 https://www.zacks.com/stock/news/2804834/how-abbvies-pipeline-is-lining-up-key-product-launches?cid=sm-stocktwits-2-2804834-body-24944&ADID=SYND_STOCKTWITS_TWEET_2_2804834_BODY_24944
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 16 at 1:39 PM
$NKTR Immuno detm enrolled some incorrect patients. Indicating; UP conf call ongoing. After determinined incorrect, they were excluded from study. “17% delta in ITT population is solid, definitely active, and meets the sellside bar of >15%. However, on the call we will hopefully see what the reasons were for the erroneously enrolled ineligible patients that supposedly brought this result lower than it should’ve been. With those 4 ineligible patients excluded from the trial this would’ve been a fantastic result with >24% delta and the stock would be up a ton. Hopefully we get some granularity on what the protocol violations on enrolling those patients were.” Mixed result given that situation. At the very least the drug is definitely active in AA, and the post JAK maintenance hypothesis is certainly well in play.” $IFRX $MLTX $ABBV $RHHBY https://ir.nektar.com/news-releases/news-release-details/rezolve-aa-phase-2b-study-rezpegaldesleukin-establishes-proof
0 · Reply
ZacksResearch
ZacksResearch Dec. 16 at 1:00 PM
$ABBV setting up a serious late-stage catalyst run 👀 The company is lining up multiple late-stage launches — including Rinvoq label expansions and Parkinson’s and oncology assets nearing FDA decisions — stacking several potential approvals at once. Get the full breakdown on what’s coming next 👉 https://www.zacks.com/stock/news/2804834/how-abbvies-pipeline-is-lining-up-key-product-launches?cid=sm-stocktwits-2-2804834-teaser-24937&ADID=SYND_STOCKTWITS_TWEET_2_2804834_TEASER_24937
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 16 at 12:13 PM
$ABBV Current Stock Price: $227.42 Contracts to trade: $230 ABBV Dec 19 2025 Call Entry: $1.48 Exit: $1.96 ROI: 32% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
V9RDPUMA
V9RDPUMA Dec. 16 at 11:45 AM
$ABBV So abbv gets an downgrade yesterday from bofa and goes up 4 points. Now I get it, upgrades bad, downgrades good. There should be a trading algo for this equation.
0 · Reply
shadowpawn
shadowpawn Dec. 16 at 2:16 AM
0 · Reply
Longbuy1
Longbuy1 Dec. 16 at 12:44 AM
$SLS $ABBV is the number one bio tech for AML, they have 5 billion in cash 401B market cap. ABBV dropping 10 bill for two best in class (possible) AML drugs dosent seem unrealistic.
0 · Reply
DeadInvestor
DeadInvestor Dec. 15 at 7:22 PM
$ALDX No idea if this will happen: I predict a 415pm news release, with approval and full label language. Then ALDX indicates $ABBV has exercised their 10-day option. Stock climbs to $15. Current market cap is $250 million. ABBV injection of $194 million should excite things!
3 · Reply
SSmicrocap
SSmicrocap Dec. 15 at 4:59 PM
$ABBV dump time
0 · Reply
Garibs
Garibs Dec. 15 at 2:52 PM
$ABBV don't let them take you red ... had good momentum for 230
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 15 at 1:31 PM
$IFRX $MLTX $ABBV $RHHBY $SNY https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.70150 “Despite standardized criteria for patient selection and outcome assessment, placebo response rates continue to demonstrate substantial variability across AD clinical trials. Recent reviews [12-14] report placebo EASI-75 response rates ranging from approximately 12% to over 20% at the primary assessment time points of Week 12 and Week 16. This variability introduces challenges when evaluating the efficacy of novel therapeutic agents, as it can lead to failed studies despite genuine therapeutic benefits by confounding treatment effect estimates with unexpectedly high placebo responses.”
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 15 at 11:05 AM
$ABBV RSI: 30.79, MACD: -0.7212 Vol: 4.12, MA20: 228.43, MA50: 227.09 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 5:34 AM
Actionable Trade Alert for $ABBV: Market Context: $ABBV is currently trading at $223.32, showing a bearish sentiment with an RSI of 30.79, indicating oversold conditions. The stock is below both the 30-day MA of 225.96 and the 50-day MA of 227.35, suggesting continued downward pressure. However, the price is near the 60-day low of 211.69, which could present a potential reversal opportunity. Directional Bias: Given the oversold RSI and proximity to the 60-day low, there is a chance for a bullish reversal. Trade Plan: - Suggested Entry: $223.32 - Stop Loss: $210.00 (below the 60D low for risk management) - Take Profit Targets: - TP1: $230.00 (3% gain) - TP2: $240.00 (7.5% gain) - TP3: $260.00 (16.5% gain) With a potential ROI of over 17% on TP3, this trade offers a favorable risk-reward ratio. Monitor the price action closely for confirmation of the bullish reversal. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply